In which cancer is MyChoice CDx used?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $24.99Unlock all

Unlock essential insights into hereditary cancer risk, diagnosis, and treatment. Study comprehensive strategies with flashcards and multiple-choice questions featuring detailed explanations. Prepare effectively for your exam!

Multiple Choice

In which cancer is MyChoice CDx used?

Explanation:
The main idea is how a companion diagnostic like MyChoice CDx is used to identify tumors that may respond to targeted therapy. MyChoice CDx is designed to assess homologous recombination deficiency (HRD) and BRCA1/2 mutation status in tumor tissue. In ovarian cancer—especially high-grade serous cases—HRD is common and predicts sensitivity to PARP inhibitors. Because of this, MyChoice CDx is used to select ovarian cancer patients who are likely to benefit from PARP inhibitor therapy, guiding treatment decisions such as maintenance after platinum-based chemotherapy. While PARP inhibitors are also used in breast, prostate, and pancreatic cancers, those settings rely on different testing approaches (often BRCA1/2 mutation testing or other HRD assessments specific to those contexts). The MyChoice CDx test is specifically aligned with guiding PARP inhibitor use in ovarian cancer.

The main idea is how a companion diagnostic like MyChoice CDx is used to identify tumors that may respond to targeted therapy. MyChoice CDx is designed to assess homologous recombination deficiency (HRD) and BRCA1/2 mutation status in tumor tissue. In ovarian cancer—especially high-grade serous cases—HRD is common and predicts sensitivity to PARP inhibitors. Because of this, MyChoice CDx is used to select ovarian cancer patients who are likely to benefit from PARP inhibitor therapy, guiding treatment decisions such as maintenance after platinum-based chemotherapy.

While PARP inhibitors are also used in breast, prostate, and pancreatic cancers, those settings rely on different testing approaches (often BRCA1/2 mutation testing or other HRD assessments specific to those contexts). The MyChoice CDx test is specifically aligned with guiding PARP inhibitor use in ovarian cancer.

More Multiple Choice Questions
Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy